Merck KGaA wins GSK for immunotherapy deal worth up to $4.2 billion

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.22 billion) to Germany's Merck KGaA for the rights to a novel immunotherapy.